AL型淀粉样变性干细胞移植后血液学反应与生存的预测因素:一项25年纵向研究
该研究报告了648例接受HDM/SCT治疗的AL型淀粉样变性患者25年长期结局。39%患者达血液学完全缓解,中位缓解持续12.3年;中位无事件生存期和总生存期分别为3.3年和7.6年。多因素分析确定dFLC>180 mg/L和骨髓浆细胞>10%为无事件生存期独立不良因素,并据此建立预后评分。
要点
- 39%患者达血液学完全缓解,中位缓解持续12.3年,45%在15年时无复发证据
- 中位随访8年,中位无事件生存期3.3年,中位总生存期7.6年
- 预后评分低危(0因素)、中危(1因素)、高危(2因素)中位无事件生存期分别为5.3、2.8、1.0年(p<.001)
核心结论
- HDM/SCT可在部分AL型淀粉样变性患者中诱导持久血液学反应并延长生存,且安全性改善。
研究设计与样本
- 回顾性纵向研究,纳入25年间接受HDM/SCT治疗的648例AL型淀粉样变性患者。
主要发现
- 39%患者达血液学完全缓解,中位缓解持续12.3年,45%的完全缓解者在移植后15年无复发性浆细胞病证据。
- 中位随访8年,中位无事件生存期3.3年,中位总生存期7.6年;达血液学完全缓解者中位总生存期15年,30%生存超过20年。
- 多因素分析显示dFLC>180 mg/L和骨髓浆细胞>10%与较短无事件生存期独立相关;BNP>81 pg/mL、肌钙蛋白I>0.1 ng/mL和血清肌酐>2.0 mg/dL与较短总生存期独立相关。
- 预后评分低危(0因素)、中危(1因素)、高危(2因素)中位无事件生存期分别为5.3年、2.8年、1.0年(p<.001)。
- 最近治疗时期(2012-2021年)100天治疗相关死亡率为3%,25年治疗相关髓系肿瘤/急性髓系白血病风险为3%。
关键数值与推荐
- 无事件生存期预后评分纳入dFLC>180 mg/L和骨髓浆细胞>10%作为不良危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-dose melphalan and stem cell transplantation (HDM/SCT) is an effective treatment for selected patients with AL amyloidosis. We report the long-term outcomes of 648 patients with AL amyloidosis treated with HDM/SCT over 25 years. Hematologic CR was achieved by 39% of patients. The median duration of hematologic CR was 12.3 years, and 45% of patients with a hematologic CR had no evidence of a recurrent plasma cell dyscrasia at 15 years after HDM/SCT. With a median follow-up interval of 8 years, the median event-free survival (EFS) and overall survival (OS) were 3.3 and 7.6 years, respectively. Patients with a hematologic CR had a median OS of 15 years, and 30% of these patients survived >20 years. On multivariable analysis, dFLC >180 mg/L and BM plasma cells >10% were independently associated with shorter EFS, whereas BNP >81 pg/mL, troponin I > 0.1 ng/mL, and serum creatinine >2.0 mg/dL were independently associated with shorter OS. We developed a prognostic score for EFS, which incorporated dFLC >180 mg/L and BMPC% >10% as adverse risk factors. Patients with low-risk (0 factors), intermediate-risk (1 factor), and high-risk (2 factors) disease had median EFS estimates of 5.3, 2.8, and 1.0 years, respectively (p < .001). The 100-day treatment-related mortality rate was 3% in the latest treatment period (2012-2021), and the 25-year risk of t-MDS/AML was 3%. We conclude that HDM/SCT induces durable hematologic responses and prolonged survival with improved safety in selected patients with AL amyloidosis.
引用
- Gustine JN, Staron A, Szalat RE, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022. PMID: 35731907. doi:10.1002/ajh.26641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。